时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Cutaneous squamous cell carcinoma (CSCC) represents the second most common skin cancer worldwide, accounting for approximately 20% of all keratinocyte-derived malignancies ().；It is estimated that more than 1 million cases of CSCC occur annually in the United States.
方法
The CSCC mortality rate among individuals aged 65 or older increases progressively with age, rising from 2.5 per 100, 000 population in those aged 65–69 to 21.28 per 100, 000 in those aged 95 years or older.；Surgical management of these higher-risk CSCC usually requires more extensive resections followed by adjuvant radiotherapy.；These responses have frequently proven durable, with longer-term follow-up (, ).
核心结论
The CSCC mortality rate among individuals aged 65 or older increases progressively with age, rising from 2.5 per 100, 000 population in those aged 65–69 to 21.28 per 100, 000 in those aged 95 years or older.；Although surgery or radiotherapy remain standard treatment for most patients with small primary CSCC, a minority of patients present with locoregionally advanced disease, representing approximately 2-5% of all cases (, ).；Surgical management of these higher-risk CSCC usually requires more extensive resections followed by adjuvant radiotherapy. ‖ 结论：However, given the small number of patients in this case report with relatively short follow-up, our results should be considered hypothesis-generating.
局限
Response adapted studies such as De-Squamate offer preliminary support for surgical omission in patients with rigorously confirmed responses ().；Critical unanswered questions include how to exclude residual primary and nodal disease, which patients can safely avoid local therapy, and how long immunotherapy should continue after apparent remission.
对本项目的价值
★☆☆☆☆ 相关范围内，作为背景与横向对照收录。
全文来源
PMC JATS 全文（正文 16,737 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Case Report: Improvement in neurologic symptoms and remission following non-operative management of locally advanced cutaneous squamous cell carcinoma of the head and neck following cemiplimab therapy: two cases.
- 期刊与标识：Front Oncol · PMID 42959034 · DOI 10.3389/fonc.2026.1975694
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。